Read an article published in BioProcess International which explores Cynata’s interest in this area.
Finance News Network discusses with Cynata CEO Dr Ross Macdonald the Company’s 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform
Ed Miseta, Clinical Leader’s Chief Editor, discusses Cynata’s osteoarthritis clinical program and general therapeutic stem cell topics with Cynata’s CEO, Dr Ross Macdonald and COO, Dr Kilian Kelly.
In this interview Ross Macdonald discusses Cynata’s unique approach to the manufacture of therapeutic mesenchymal stem/stromal cells from induced pluripotent stem cells and why this provides the Company with an important competitive advantage.
Source: Licensing Executives Society (LEX) Newsstand - Powered by Lexology
In 2014, Cynata Therapeutics commenced technology transfer and product development, and simultaneously commenced consultation with regulatory authorities regarding the approval pathways for its cellular therapy products.